FDA Approved: INVOKAMET — Supplemental Application (Janssen Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for INVOKAMET, Janssen’s fixed-dose combination of canagliflozin and metformin hydrochloride.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Invokamet (canagliflozin and metformin hydrochloride)

Snippet

SUPPL AP for INVOKAMET (CANAGLIFLOZIN AND METFORMIN HYDROCHLORIDE)